Open AccessCross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination
Author(s) -
Yukiya Kurahashi,
Koichi Furukawa,
Silvia Sutandhio,
Lidya Handayani Tjan,
Sachiyo Iwata,
Shigeru Sano,
Yoshiki Tohma,
Hiroyuki Ohkita,
Sachiko Nakamura,
Mitsuhiro Nishimura,
Jun Arii,
Tatsunori Kiriu,
Masatsugu Yamamoto,
Tatsuya Nagano,
Yoshihiro Nishimura,
Yasuko Mori
Publication year - 2022
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiac178
Subject(s) - neutralizing antibody , vaccination , titer , covid-19 , virology , medicine , antibody , messenger rna , coronavirus , immunology , disease , biology , infectious disease (medical specialty) , gene , biochemistry
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant omicron is now under investigation. We evaluated cross-neutralizing activity against omicron in coronavirus disease 2019 (COVID-19) convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including omicron, all became seropositive, and significant fold-increases (21.1-52.0) were seen regardless of the disease severity. Our findings thus demonstrate that 2 doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against omicron.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom